Sutro Biopharma Expected to Report $3.77 Per Share Loss, Revenue Down 54%
summarizeSummary
Sutro Biopharma is expected to report a loss of $3.77 per share for the quarter ending March 31, 2026, with analyst consensus projecting a 53.6% decrease in revenue to $8.079 million. These estimates precede the company's anticipated earnings release on May 6. This preview provides critical financial expectations for the upcoming quarter, following the company's reported $191.1 million net loss for the full year 2025. While these are analyst estimates, they establish the benchmark for the actual earnings report, and any significant deviation could lead to notable stock movement, particularly as the stock is trading near its 52-week high. Traders will closely monitor the actual earnings release for surprises relative to these expectations and management's commentary on pipeline progress and cash burn.
At the time of this announcement, STRO was trading at $38.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $589.6M. The 52-week trading range was $6.74 to $39.10. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.